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Abstract. Using localized proton magnetic resonance 
spectroscopy ('H-MRS), accumulation of branched- 
chain amino acids (BCAA) and their corresponding 2- 
oxo acids (BCOA) could be non-invasively demonstrat­
ed in the brain of a 9-year-old girl suffering from classi­
cal maple syrup urine disease. During acute metabolic 
decompensation, the compounds caused a signal at a 
chemical shift of 0.9 ppm which was assigned by in vitro 
experiments. The brain tissue concentration of the sum 
of BCAA and BCOA could be estimated as 0.9 mmol/1. 
Localized ^-MRS of the brain appears to be suitable 
for examining patients suffering from maple syrup urine 
disease in different metabolic states.
Localized proton magnetic resonance spectroscopy (rH- 
MRS) of the brain allows the non-invasive study of me­
tabolic disorders in vivo [1-3]. Maple syrup urine dis­
ease (MSUD; McKusick 24860) is characterized by 
acute and chronic brain dysfunction due to accumula­
tion of branched-chain amino acids (BCAA) and their
2-oxo acids (BCOA) caused by a defect of the oxidative 
decarboxylation of leucine, isoleucine, and valine [4, 5].
In this study, we present the results of an MRS exam­
ination of the brain of a 9-year-old girl suffering from 
classic MSUD, during an acute metabolic decompensa­
tion. The accumulation of the pathologic metabolites 
within cerebral tissue was demonstrated non-invasively. 
The concentration of the sum of BCAA and BCOA 
could be estimated using in vivo ^ - M R  spectroscopy.
Patients and methods
The plasma concentrations of B C A A  were determined by auto­
mated amino acid analysis, and of BCOA as quinoxalinole deriva­
tives by a high-performance liquid chromatography (HPLC) m eth­
od [6], Image-guided volume-selective ^ - M R S  measurements 
were performed using a clinical 1.5-T whole-body M R system
Fig. 1. T2-weighted axial MR 
image from a 9-year-old girl 
suffering from classic MSUD. 
The rectangle indicates the vo­
lume selected for localized 1H- 
MR spectroscopy
(Gyroscan S 15, Philips, Best, The Netherlands) operating at 
63.86 MHz for protons. TH imaging preceded spectroscopy to de­
fine the volume of interest. The spectrum was taken from a 
3 x 3 x 7  cm3 volume located in the parieto-occipital region of the 
patient's brain (see Fig. 1).
Volume-selective ]H spectra were achieved using a spatially se­
lective 90°~180°-180° spin-echo sequence [7, 8] with water sup­
pression by selective inversion. The applied spin-echo times (TE) 
of 136 ms resulted in inversion of doublets with spin-spin couplings 
of about 7.35 Hz (e. g. lactate and amino acids as leucine, isoleu­
cine, valine! and the related 2-oxo derivatives), A  repetition time 
(TR) of 2 s resulted in a total acquisition time of 8 min 32 s for 
25Ó scans.
Spectra were evaluated quantitatively after Lorentzian broad­
ening of 2 Hz and phase correction by comparing peak areas, 
which were calculated using the product of peak height and full 
line width at half maximum, assuming Lorentzian line shape.
Spectra from six additional children of between 4.5 and
14.5 years of age, without known metabolic disorders, taken under 
the same conditions were available for comparison.
Results
Correspondence to: W. Heindel
The 9-year-old patient presented with high fever, vomit­
ing and moderate ataxia during acute metabolic decom­
pensation of known classic MSUD, diagnosed in the
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Fig. 2 a. Proton MR spectrum from a 9-year-old girl with classic 
M SUD. Spectrum of predominantly white matter from a 63-ml vo­
lume indicated in Fig.l; b the same spectrum after magnification 
of the intensity axis by a factor of 3
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Fig. 3 a, b. Proton MR spectrum from a 5-year-old boy without me­
tabolic disorders, a The sizes of the Cr and Cho signals are mat­
ched to the corresponding signals in Fig. 2; b the same spectrum 
after magnification of the intensity axis by a factor of 3. The signal 
at 0.9 ppm is significantly smaller than in the spectrum from the pa­
tient suffering from MSUD
neonatal period when she sufferend from metabolic 
coma. A t the time of admission, the plasma concentra­
tions of BCAA were found to be elevated: Leu, 
1023 [xmol/1; Val, 692 jimol/1; lie, 290 [xmol/1, compared 
with normal concentration ranges: Leu, 77-173 (xmol/1; 
Val, 167-265 (xmol/1; lie, 30-71 fimol/l [9]. Oral feeding
was stopped, and high-caloric parenteral nutritition 
was started immediately. During the following days, 
oral feeding was reintroduced, using a diet extremely re­
duced in leucine.
Seven days after admission, ^-M R S  of the brain was 
performed. A t that time the patient showed only mild 
ataxia and she was being fed completely orally. The plas-
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was assigned to the methyl residues of BCAA and 
BCOA, based on its chemical shift and the fact that the 
signal was inverted at the echo time of 136 ms, which in­
dicates a spin-spin coupling of about 7 Hz. To confirm 
the assignment, pure 2-oxo-isocaproic acid as well as 
pure leucine, which contribute the largest amount to 
the signal in question, were dissolved in demineralized 
water and adjusted to neutral pH. In vitro spectra of 
the solutions were obtained using the same volume-se- 
lection method and echo time (Fig. 4).
A  signal intensity ratio (BCAA + BCOA)/Cr of 0.20 
was calculated for the patient. In spectra of healthy chil­
dren this signal was found only in low intensities 
((BCAA + BCOA)/Cr < 0.1, Fig,3).
A  further inverted signal at 1.6 ppm in the patient’s 
spectrum could not be assigned.
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Fig. 4 a, b. Proton MR spectra of aqueous solutions of a leucine 
and b 2-oxo-isocaproic acid, obtained with an echo time of 
TE = 136 ms and phased according to the spectrum shown in Fig. 2
ma concentrations of BCAA and their corresponding 
BCOA were still high: Leu, 1143 jxmol/1; 2-oxo-iso­
caproic acid, 497 (xmol/1; Val, 487 ¡xmol/I; 2-oxo-isovale- 
ric acid, 49 ¡imol/1; lie, 259 ^mol/1; 2-oxo-3-methyl- 
valeric acid, 101 [imol/L Normal plasma concentrations 
of BCOA are: 2-oxo-isocaproic acid, 42 [xmol/1; 2-oxo- 
isovaleric acid, 15 fxmol/1; 2-oxo-3-methylvaleric acid,
20 (junolA [10].
M R imaging showed normal intracerebral structures, 
and no abnormalities of cerebral white and grey matter 
could be detected.
Fig. 1 shows a representative T2-weighted axial im­
age, which was used to select a rectangular volume com­
prising predominantly occipital white matter for spec­
troscopy. The proton spectrum of this patient (Fig. 2 a) 
shows relative signal intensities of N-acetyl-aspartate 
(NAA), choline (Cho) and creatine (Cr) quite compara­
ble to findings in normal subjects (Fig. 3). The ratios are
NAA/Cho = 1.37, NAA/Cr = 1.98, Cr/Cho = 0.70. In
addition, the spectrum exhibited a small but distinct in­
verted signal at a chemical shift of 0.9 ppm, which be­
comes evident after magnification (Fig. 2 b). This signal
Discussion
In MSUD, acute metabolic decompensation leads to ac­
cumulation of BCAA and their BCOA in brain tissue, 
resulting in both short-term and long-lasting cerebral 
impairment. M RI studies report on dysmyelination of 
the white matter and abnormalities of grey matter, par­
ticularly the globi pallidi [11].
In the child presented here, morphological changes 
could not be observed. However, lH-MRS provided in­
formation on increased concentrations of BCAA and 
BCOA in the brain in a non-invasive manner. Similar 
results have recently been reported by another group
[12]. However, in contrast to the spectra of the patient 
described by Felber et al. [12], in the brain tissue of our 
patient no signal of lactic acid was found by ^I-MRS, 
possibly reflecting the lower degree of metabolic distur­
bances.
The concentration of BCAA and BCOA in the brain 
tissue may be estimated from the intensity of their me­
thyl residue resonance.
Using creatine as an internal concentration standard 
with an assumed brain tissue concentration of 9 mmol/1
[13], the concentration for the sum of BCAA and 
BCOA can be calculated as 0,9 mmol/1. This value ac­
counts for the fact that six protons contribute to the sig­
nal instead of three as in the case of creatine. A correc­
tion for relaxation and saturation effects is not feasible, 
as T1 and T2 values are not known for BCAA in brain 
tissue. We assume that the relaxation times of BCAA 
and creatine are comparable, as the sizes of the mole­
cules are in the same order, so that the error from this 
source would be minor. The concentration may be un­
derestimated, however, owing to incomplete spectral 
visibility and incomplete refocusing of methyl residue 
doublets. In the brain tissue, the true JJ coupling con­
stants may not match exactly the 7.3 Hz of lactate, for 
which the standard spectroscopic measurement proto­
col is optimized.
In comparison, in the spectrum of a subject without 
metabolic disorders given in Fig. 3, the resonance at
0.9 ppm indicates an amount of spectroscopically visible 
BCAA of less than 0.4 mmol/1 in brain tissue.
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The measured signals represent metabolite content 
of brain tissue, while only plasma values are available 
from biochemical assays. As has been shown for glycine, 
brain tissue concentrations of amino acids are usually in 
the same order of magnitude as plasma concentrations 
[3], In the child without metabolic disorders, the sum of 
normal plasma concentrations of BCAA and BCOA, 
as assumed to be present in this case, range from 350 to 
590 [imol/1. This is an accordance with the brain tissue 
concentration of less than 0.4 mmol/1 estimated from 
the MR spectrum. The plasma concentration of the pa­
tient was 2536 ¡amol/1 on the day of the MR examina­
tion. The brain tissue concentration of 0.9 mmol/1 esti­
mated from the spectrum is well below this value. This 
may reflect incomplete visibility of the amino acids or 
underestimation due to a systematic error. The increase 
over normal values is clearly detectable, however.
In conclusion, localized ^-M RS of the brain serves 
as a non-invasive tool to obtain information on BCAA 
and BCOA concentrations in the brain tissue in differ­
ent metabolic states. Our preliminary data indicate that 
rH-MRS may be useful in evaluating the state of disease 
in  MSUD and response to therapy.
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